Transce3nd’s Harvard Bioscience HBIO Stock Holding History

Transce3nd’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-94	Closed	-$416	–	578
2025 Q2	$416	Hold	94	–	–	﹤0.01%	1110
2025 Q1	$531	Hold	94	–	–	﹤0.01%	1029
2024 Q4	$1.98K	Buy	+94	New	+$2.16K	﹤0.01%	1108

Other funds holding HBIO

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Transce3nd's HBIO Position: Q3 2025 in Review

Transce3nd sold out of Harvard Bioscience (HBIO) in Q3 2025, closing a stake of 94 shares — an estimated $416 sold.

Transce3nd first reported a position in HBIO in Q4 2024 and held it in 3 quarters. The position peaked at $1.98K in Q4 2024. 59 funds tracked by Wall St. Rank hold HBIO as of Q3 2025.

Transce3nd reported no remaining Harvard Bioscience position as of Q3 2025 after selling out during the quarter.
Transce3nd sold 94 Harvard Bioscience shares in Q3 2025, an estimated $416.
Transce3nd first reported a position in Harvard Bioscience in Q4 2024 and held it in 3 quarters.
Transce3nd's Harvard Bioscience position peaked at $1.98K in Q4 2024.
59 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.